ArticleCureus2025
Autoimmune Epilepsy Secondary to CASPR2 Antibody Encephalitis: A Case Report Highlighting Diagnostic Challenges and Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CASPR2 (contactin-associated protein-like 2) is a cell adhesion molecule expressed in both the central and peripheral nervous systems. CASPR2 autoantibodies are associated with autoimmune encephalitis and epilepsy; however, the initial presentation and subsequent treatment can be challenging. We report a rare case of CASPR2-related new-onset seizures, culminating in a motor vehicle accident, as well as dysautonomia in a 50-year-old man with a prior history of vasovagal syncope. The patient experienced three types of seizures: (i) focal preserved consciousness seizures, (ii) focal preserved consciousness seizures/dysautonomia, and (iii) focal impaired consciousness seizures. Post-ictal confusion included stripping clothes off due to feeling hot. Video electroencephalogram (EEG) monitoring confirmed bilateral temporal lobe seizures. Further evaluation revealed anti-CASPR2 antibody positivity in both serum and cerebrospinal fluid (CSF), consistent with autoimmune epilepsy. Despite treatment with intravenous (IV) methylprednisolone (1 g/day for five days) and multiple antiseizure medications (levetiracetam, lacosamide, and oxcarbazepine), the patient experienced persistent recurrent seizures, cognitive deficits, and medication-related side effects. This prompted adding IV immunoglobulin therapy, which helped with seizure control. This case underscores the diagnostic challenges of CASPR2 autoimmune epilepsy and highlights the importance of early recognition and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.